Yipinhong Pharmaceutical Co Ltd Class A (SHE:300723) — Market Cap & Net Worth
Market Cap & Net Worth: Yipinhong Pharmaceutical Co Ltd Class A (300723)
Yipinhong Pharmaceutical Co Ltd Class A (SHE:300723) has a market capitalization of $2.21 Billion (CN¥15.10 Billion) as of October 13, 2026. Listed on the SHE stock exchange, this China-based company holds position #5777 globally and #1063 in its home market, demonstrating a -2.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yipinhong Pharmaceutical Co Ltd Class A's stock price CN¥33.42 by its total outstanding shares 451692766 (451.69 Million).
Yipinhong Pharmaceutical Co Ltd Class A Market Cap History: 2017 to 2026
Yipinhong Pharmaceutical Co Ltd Class A's market capitalization history from 2017 to 2026. Data shows growth from $843.63 Million to $2.21 Billion (16.27% CAGR). Check Yipinhong Pharmaceutical Co Ltd Class A stock price for real-time trading data and today's change.
Yipinhong Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 300723 cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
2.38x
Yipinhong Pharmaceutical Co Ltd Class A's market cap is 2.38 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $843.63 Million | $1.38 Billion | $156.70 Million | 0.61x | 5.38x |
| 2018 | $629.59 Million | $1.43 Billion | $208.22 Million | 0.44x | 3.02x |
| 2019 | $908.89 Million | $1.64 Billion | $143.69 Million | 0.56x | 6.33x |
| 2020 | $956.84 Million | $1.68 Billion | $225.61 Million | 0.57x | 4.24x |
| 2021 | $1.55 Billion | $2.20 Billion | $306.92 Million | 0.70x | 5.04x |
| 2022 | $1.50 Billion | $2.28 Billion | $290.68 Million | 0.66x | 5.16x |
| 2023 | $1.95 Billion | $2.50 Billion | $184.61 Million | 0.78x | 10.58x |
| 2024 | $1.13 Billion | $1.45 Billion | -$540.04 Million | 0.78x | N/A |
| 2025 | $2.22 Billion | $932.27 Million | -$337.79 Million | 2.38x | N/A |
Competitor Companies of 300723 by Market Capitalization
Companies near Yipinhong Pharmaceutical Co Ltd Class A in the global market cap rankings as of October 13, 2026. See Yipinhong Pharmaceutical Co Ltd Class A balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to Yipinhong Pharmaceutical Co Ltd Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #526 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #585 globally with a market cap of $46.39 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #628 globally with a market cap of $43.73 Billion USD ( CN¥298.86 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #630 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #526 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #585 | GALDERMA GROUP AG | NYSE:GALDY | $46.39 Billion | $39.79 |
| #628 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.73 Billion | CN¥46.85 |
| #630 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.30 |
Yipinhong Pharmaceutical Co Ltd Class A Historical Marketcap From 2017 to 2026
Between 2017 and today, Yipinhong Pharmaceutical Co Ltd Class A's market cap moved from $843.63 Million to $ 2.21 Billion, with a yearly change of 16.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.21 Billion | -0.39% |
| 2025 | CN¥2.22 Billion | +96.66% |
| 2024 | CN¥1.13 Billion | -42.27% |
| 2023 | CN¥1.95 Billion | +30.21% |
| 2022 | CN¥1.50 Billion | -3.00% |
| 2021 | CN¥1.55 Billion | +61.63% |
| 2020 | CN¥956.84 Million | +5.28% |
| 2019 | CN¥908.89 Million | +44.36% |
| 2018 | CN¥629.59 Million | -25.37% |
| 2017 | CN¥843.63 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 12th, 2026 the market cap of Yipinhong Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.21 Billion USD |
| MoneyControl | $2.21 Billion USD |
| MarketWatch | $2.21 Billion USD |
| marketcap.company | $2.21 Billion USD |
| Reuters | $2.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale a… Read more